Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial
Pharmaceutical Technology
JUNE 16, 2023
The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs). The developer has tested OVX836 in four completed clinical trials. The aim of the latest ongoing trial is to evaluate the vaccine in a larger and more diverse population.
Let's personalize your content